N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal
dysfunction in patients with rheumatic valvular heart disease undergoing single valve
replacement.